Edgewise Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Provided By PR Newswire
Last update: Aug 7, 2025
– Announced positive top-line data from the open-label extension MESA trial of sevasemten in participants with Becker muscular dystrophy who previously completed ARCH and CANYON studies –
Read more at prnewswire.com
